Filtered By:
Condition: Thrombosis
Drug: Pradaxa
This page shows you your search results in order of date. This is page number 10.
Order by Relevance | Date
Total 508 results found since Jan 2013.
Thrombin in complex with dabigatran can still interact with PAR-1 via exosite-I and instigate loss of vascular integrity
CONCLUSIONS: Proteolytically inactive thrombin in complex with dabigatran evokes loss of barrier function that can be prevented by a PAR-1 mimicking peptide blocking thrombin's exosite-I.PMID:35037739 | DOI:10.1111/jth.15642
Source: Thrombosis and Haemostasis - January 17, 2022 Category: Hematology Authors: Sophie C D ólleman Stijn M Agten Henri M H Spronk Tilman M Hackeng Mettine H A Bos Henri H Versteeg Anton Jan van Zonneveld Hetty C de Boer Source Type: research
Fatal Adverse Events of Dabigatran Combined With Aspirin in Elderly Patients: An Analysis Using Data From VigiBase
Conclusion: The fatal adverse events associated with the combined use of dabigatran and aspirin in elderly patients were mainly serious bleeding events, which often occurred within 1 month. Most of these cases had medication errors and most of the patients had multiple diseases, medications, or other conditions at the same time that increase the risk of bleeding. It is suggested that prescription of dabigatran and aspirin in elderly patients should go along with alertness for medication errors, care for correct dose or control of other bleeding risk factors, and the combined medication time should be as short as possible ...
Source: Frontiers in Pharmacology - December 22, 2021 Category: Drugs & Pharmacology Source Type: research
Evaluation of rivaroxaban-, apixaban- and dabigatran-associated hemorrhagic events using the FDA-Adverse event reporting system (FAERS) database
Conclusions Overall, we found a moderate signal of higher frequency of reporting hemorrhage in rivaroxban compared with dabigatran and decreased hemorrhagic event reporting in apixaban compared with dabigatran. While this potential signal has not been confirmed in clinical trials or observational studies, in clinical practice, attention should be paid to the risk of potential hemorrhage when the patients switch from apixaban to dabigatran or rivaroxban.
Source: International Journal of Clinical Pharmacy - December 1, 2021 Category: Drugs & Pharmacology Source Type: research
Risk of stroke and other thromboembolic complications after interruption of DOAC therapy compared with warfarin therapy in patients with atrial fibrillation: a retrospective cohort analysis
This study did not find a significant difference in the complication rate after interruption of DOAC therapy compared with interruption of warfarin therapy in hospitalized patients with a high risk of thromboembolism.
Source: Journal of Investigative Medicine - November 25, 2021 Category: Research Authors: Hellerman Itzhaki, M., Greenberg, N., Margalit, I., Shochat, T., Krause, I., Goldberg, E. Tags: Original research Source Type: research
Safety and efficacy of low-dose non-vitamin K antagonist oral anticoagulants versus warfarin after left atrial appendage closure with the Watchman device
CONCLUSION: The safety and efficacy of low-dose dabigatran and rivaroxaban were comparable to those of warfarin within 45 days after Watchman device implantation in a Chinese population.PMID:34740490 | DOI:10.1016/j.jfma.2021.10.015
Source: J Formos Med Assoc - November 6, 2021 Category: General Medicine Authors: Guohua Fu Binhao Wang Bin He Yibo Yu Zhao Wang Mingjun Feng Jing Liu Xianfeng Du Weidong Zhuo Huimin Chu Source Type: research
Nonvitamin K Antagonist Oral Anticoagulant in Patients With Venous Thromboembolism and Polycythemia Vera or Essential Thrombocythemia: A Cohort Study
This study shows that NOACs may be effective and safe as secondary prevention of VTE in patients with myeloproliferative neoplasms.
Source: Journal of Cardiovascular Pharmacology - November 1, 2021 Category: Cardiology Tags: Original Article Source Type: research
Short- and long-term outcome of patients with spontaneous echo contrast or thrombus in the left atrial appendage in the era of the direct acting anticoagulants
ConclusionEven in the DOAC era, the occurrence of thrombus or SEC in the LAA is associated with a high rate of MACCE. Our study suggests that the choice of DOAC therapy may have an impact on long-term survival.Graphic abstract
Source: Clinical Research in Cardiology - November 1, 2021 Category: Cardiology Source Type: research
Medication errors associated with direct-acting oral anticoagulants: analysis of data from national pharmacovigilance and local incidents reporting databases
ConclusionsThis observational study demonstrates the nature of DOAC related medication errors in clinical practice. Developing risk prevention and reduction strategies using the expertise of clinical pharmacists are imperative in promoting patient safety associated with DOAC use.
Source: Journal of Pharmaceutical Policy and Practice - October 1, 2021 Category: Pharmaceuticals Source Type: research
Effectiveness and Safety of Dabigatran in Atrial Fibrillation Patients with Severe Obesity: a Real-World Retrospective Cohort Study
ConclusionsAmong AF patients with a BMI>40kg/m2 or a weight>120kg in a real-world clinical setting, dabigatran was effective in reducing the risk of thromboembolism and mortality but was associated with an increased risk of bleeding when compared to warfarin. Dabigatran may be a reasonable option for AF patients with severe obesity.
Source: Journal of General Internal Medicine - September 20, 2021 Category: Internal Medicine Source Type: research
A Review of Direct Oral Anticoagulants in Patients With Stage 5 or End-Stage Kidney Disease
CONCLUSIONS: If OACs for stroke prevention with AF are deemed necessary, apixaban or rivaroxaban can be considered. DOACs cannot currently be recommended over warfarin in patients with CKD-5 or ESKD and VTE.PMID:34459281 | DOI:10.1177/10600280211040093
Source: The Annals of Pharmacotherapy - August 30, 2021 Category: Drugs & Pharmacology Authors: Jessica A Starr Nathan A Pinner Melanie Mannis Mary Katherine Stuart Source Type: research
Short- and long-term outcome of patients with spontaneous echo contrast or thrombus in the left atrial appendage in the era of the direct acting anticoagulants
ConclusionEven in the DOAC era, the occurrence of thrombus or SEC in the LAA is associated with a high rate of MACCE. Our study suggests that the choice of DOAC therapy may have an impact on long-term survival.Graphic abstract
Source: Clinical Research in Cardiology - August 26, 2021 Category: Cardiology Source Type: research
